News

Both, PSP and CBD represent diseases of the central nervous system and are collectively called as tauopathies, and for which no FDA approved therapies exist. The Phase I

Andexanet alfa is Portola’s investigational Factor Xa inhibitor antidote and edoxaban is Daiichi Sankyo’s Factor Xa inhibitor. The two firms have signed original collaboration agreement in June 2013

The trial of RGN-259 (a Thymosin Beta 4-based preservative-free eye drop) is based on data secured from a 72-patient, double-masked, placebo-controlled trial sponsored by RegeneRx and conducted by

Daklinza is a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), while Sunvepra is a NS3/4A protease inhibitor. Currently there are no treatment options for this disease in

GSK noted that trametinib has not showed clinical activity in patients who have progressed on a prior BRAF inhibitor therapy. The EU approval is based on results from

The deal focuses on endometriosis and uterine fibroids with the goal of discovering and developing new treatment options for these diseases. Bayer HealthCare member of the executive committee

The company said that prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these

The CHMP concluded that the benefits of Seasonique outweigh its risks clearing the way for the drug’s approval by local health authorities of the European Union (EU) Member

Investigator Peter Humphrey and his wife Yu Yingzeng were arrested by Chinese police in July 2013 following work they did for GSK. GSK hired Humphrey’s Chinese corporate investigations